Is Jakafi Right for Me?

How do I know if I am a possible candidate for Jakafi?

Jakafi® (ruxolitinib) is an FDA-approved treatment option for adults with certain types of myelofibrosis (MF) and is included as part of national treatment recommendations for patients with intermediate or high-risk MF.

Your individual MF treatment options depend on your specific MF risk level and the severity of your symptoms.

If you have intermediate or high-risk MF, Jakafi may be a possible treatment option for you. Talk to your Healthcare Professional to learn what may be possible with Jakafi.

Patient Perspectives: Mayra’s Story

image of Mayra

Mayra thought her MF symptoms were just a part of getting older. Learn how she discovered what was possible with Jakafi.

How is intermediate to high-risk MF characterized?

MF is characterized by scarring of the bone marrow (fibrosis), spleen enlargement (splenomegaly), abnormal blood counts (cytopenias) and symptom burden.

People with MF fall along a spectrum that ranges from having essentially no symptoms to having severe symptoms that affect daily living and quality of life. Myelofibrosis can occur on its own (primary myelofibrosis) or can develop from other conditions.

The risk level for MF is determined by a number of risk factors that include results of laboratory tests as well as clinical evaluation of your symptoms.

What risk factors may indicate that my MF is intermediate or high risk?

There are many things that can affect the course of your MF. These are called risk factors.

Risk factors that may be considered when determining MF risk level include:

Graphic of 65+


Being over age 65

Graphic of thermometer


The presence of certain symptoms: fever, weight loss, and night sweats

Graphic of less blood cells


A low number of red blood cells based on lab testing

Graphic of more blood cells

White blood cells

Very elevated levels of white blood cells based on lab testing

Graphic of elevated blood cells


Elevated levels of immature blood cells, or blasts, based on lab testing

Graphic of fewer blood cells


Low platelet count based on lab testing

Graphic of DNA

Genetic factors

Specific genetic mutations

Graphic of blood transfusion bag

Blood transfusions

Need for blood transfusions

The number of risk factors present at the time of diagnosis can help determine how your MF will be classified and treated. It's important to be aware of how your MF may be changing over time. If you have 1 or several of the above risk factors, talk to your Healthcare Professional about your treatment possibilities. Remember, early recognition of disease progression can play an important role in how your disease may be managed.

Explore the possible benefits of Jakafi

Learn how adults in a clinical trial responded to Jakafi.

In one clinical study, it was estimated that nearly 90% of patients with primary myelofibrosis were considered to be intermediate or high risk within 1 year of their MF diagnosis.

What tools may be used to help my Healthcare Professional classify risk in MF?

Specific scoring tools may be used to determine if your MF is considered to be low, intermediate, or high risk. How your MF is classified may affect how your condition is managed.

Scoring systems may include:

  • Uses 5 specific risk factors to predict survival
  • IPSS is used to estimate prognosis at the time of diagnosis
Graphic showing icons for – 65+, thermometer, less blood cells, more blood cells and elevated blood cells
  • Uses the same 5 specific risk factors as IPSS
  • Is used to estimate prognosis at any time during your MF journey
Graphic showing icons for – 65+, thermometer, less blood cells, more blood cells and elevated blood cells
  • Uses the same 5 DIPSS risk factors, plus 3 additional risk factors
  • Builds upon DIPSS by using additional risk factors
Graphic showing icons for – 65+, thermometer, less blood cells, more blood cells and elevated blood cells PLUS fewer blood cells, DNA and blood transfusion bag icons

Since MF is a chronic, progressive disease, early prognosis and treatment are necessary for optimal management. Be sure to talk with your Healthcare Professional about how your MF is classified.

Treatment goals for MF can include:

Graphic showing MF on clipboard
Reduction of MF Symptoms
Graphic showing reduction in the size of an enlarged spleen
Reduction in the size of an enlarged spleen
Jakafi® ruxolitinib (tablets)

Learn more about how Jakafi was studied and discover what may be possible in the treatment of certain types of MF.

Explore possible benefits of Jakafi

Image of woman – Jakafi patient – talking on the phone, sitting on a park bench

Talk with a patient taking Jakafi

Register for the Incyte Mentor Program and connect with another patient taking Jakafi.

Learn How

Interested in becoming an Incyte Mentor?
Learn about the Ambassadors for Jakafi program.

Image of Sue – Watch her story and learn how her MF symptoms affected her before she started taking Jakafi.

Learn how the symptoms of MF affected Sue before she started taking Jakafi.

Discover how Sue’s MF symptoms prompted her to talk to her Healthcare Professional about moving her treatment journey forward with Jakafi.

Watch Sue’s Story

Connect With a Patient Like Sue

Connect With a
Patient Like Sue

Register for the Incyte Mentor Program and connect with another patient taking Jakafi.

Email Address

Continue Registering

Expand Collapse



Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is also used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: for certain types of MF and PV – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; and for acute GVHD – low platelet, red or white blood cell counts, infections, and fluid retention.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.